Kezar Life Sciences, Inc. (KZR) Misses Q2 EPS by 2c

Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q2 EPS of ($0.34), $0.02 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• RegenLab targets Nasdaq listing under ticker RGNA as revenues top $29 million
• Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction